8-K: TNF Pharmaceuticals Stockholders Approve Major Capital Structure Changes, Including Five-Fold Increase in Authorized Shares and Reverse Stock Split Authority

TNF Pharmaceuticals, Inc. stockholders have approved significant amendments to the company's Certificate of Incorporation, including a substantial increase in authorized common stock and authorization for a reverse stock split, alongside the re-election of its board of directors.

Summary

• TNF Pharmaceuticals, Inc. reconvened its 2025 annual meeting of stockholders on June 3, 2025, which was originally adjourned from May 20, 2025.
• Stockholders approved an amendment to the Certificate of Incorporation to increase the number of authorized common stock shares from 250,000,000 to 1,250,000,000.
• The company filed the Share Increase Amendment with the Secretary of State of Delaware on June 6, 2025.
• Stockholders authorized the Board of Directors to increase the stated value of Series F and Series F-1 Convertible Preferred Stock from $1,000 per share to a maximum of $1,125 per share.
• As a result of this approval, the stated value of Series F Preferred Stock automatically increased to $1,100 per share, effective January 1, 2025.
• Six directors – Mitchell Glass, Christopher C. Schreiber, Joshua Silverman, Jude Uzonwanne, Bill J. White, and Stephen Friscia – were re-elected to serve until the 2026 annual meeting.
• The appointment of Stephano Slack LLC as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
• Stockholders approved an amendment allowing the Board, at its discretion and prior to the one-year anniversary of approval, to effect a reverse stock split of common stock at a ratio in the range of 1-for-2 to 1-for-100.
• Stockholders also approved a proposal to adjourn the Annual Meeting to a later date if necessary for further proxy solicitation.
• As of the March 25, 2025 record date, there were 7,392,565 shares of Common Stock, 72,992 shares of Series D Preferred Stock, approximately 3,839.35 shares of Series F Preferred Stock, 2,529.71 shares of Series F-1 Preferred Stock, and 8,565 shares of Series G Preferred Stock outstanding and entitled to vote.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as all management-backed proposals passed, indicating shareholder support for the company's strategic direction and capital structure flexibility. However, the need for a large increase in authorized shares and a potential reverse stock split can be viewed with caution by investors due to potential dilution and concerns about the underlying stock price performance.

Positives

• All proposals presented at the Annual Meeting were approved by the company's stockholders, indicating strong alignment with management's strategic initiatives.
• The re-election of all six incumbent directors provides continuity and stability in the company's leadership.
• Ratification of the independent auditor ensures ongoing financial oversight and compliance.

Negatives

• The significant increase in authorized common stock from 250 million to 1.25 billion shares could lead to substantial dilution for existing shareholders if new shares are issued.
• The approval of a potential reverse stock split, while sometimes necessary for listing compliance, often signals a low stock price and can be viewed negatively by the market.

Future Outlook

The company has secured stockholder approval for a potential reverse stock split within one year, at the Board's discretion, which could impact the future trading price and liquidity of its common stock. The increased authorization of common shares and preferred stock value provides the company with greater flexibility for future capital-raising activities or strategic transactions.

Management Comments

• "The Company is authorized to issue a total of one billion three hundred million (1,300,000,000) shares, of which (i) one billion two hundred fifty million (1,250,000,000) shares shall be common stock, par value $0.001 per share (Common Stock) and (ii) fifty million (50,000,000) shares shall be preferred stock, par value $0.001 per share (Preferred Stock)." (from the Certificate of Amendment)

Industry Context

For pharmaceutical companies, especially those in development stages like TNF Pharmaceuticals, maintaining sufficient authorized shares and flexibility in capital structure is crucial for funding research and development, clinical trials, and potential commercialization efforts. The approval of a significant increase in authorized shares and the ability to conduct a reverse stock split are common maneuvers to prepare for future equity financing rounds or to meet stock exchange listing requirements, particularly if the stock price has fallen below minimum thresholds. The increase in preferred stock value also suggests potential for future preferred equity financing.

Comparison to Industry Standards

• The authorization of a reverse stock split is a common practice among small-cap biotechnology and pharmaceutical companies, particularly those listed on Nasdaq, to maintain compliance with minimum bid price requirements (e.g., Nasdaq's $1.00 minimum bid price rule). Companies like Sorrento Therapeutics (SRNE) and Athersys (ATHX) have similarly undertaken reverse stock splits to address low share prices and avoid delisting.
• Increasing authorized shares is a standard corporate action to enable future capital raises, such as public offerings or private placements, which are vital for funding the capital-intensive drug development process. This is comparable to actions taken by many clinical-stage biotechs, such as BioNTech (BNTX) or Moderna (MRNA) in their earlier stages, though the scale of increase here is notably large relative to current outstanding shares, suggesting significant future funding needs or strategic flexibility.
• The re-election of the entire board of directors is typical for companies seeking stability and continuity, especially when navigating significant corporate actions like capital structure changes. This aligns with general corporate governance practices across the industry.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Potential for significant dilution due to the large increase in authorized common shares. The reverse stock split could impact per-share price and liquidity, potentially making the stock more attractive for institutional investment or maintaining listing, but does not change underlying value. Preferred shareholders see an increase in stated value for Series F.
• **Management/Board**: The approvals grant the Board significant flexibility and discretion over the company's capital structure, empowering them to pursue future financing or strategic initiatives.
• **Creditors**: No direct impact mentioned, but a stronger equity base from potential future capital raises could indirectly improve the company's financial stability.

Next Steps

• The Board of Directors has the discretion to effect a reverse stock split of common stock at a ratio between 1-for-2 and 1-for-100 prior to the one-year anniversary of the approval date.
• The Board of Directors has the ability to further increase the stated value of Series F and Series F-1 Preferred Stock up to $1,250 per share.
• The company may proceed with future equity offerings or other capital-raising activities utilizing the newly authorized shares.

Key Dates

Recommendation

Keywords

SEC filing, 8-K, stockholder meeting, authorized shares, common stock, preferred stock, reverse stock split, corporate governance, dilution, board of directors, auditor ratification, TNF Pharmaceuticals